デフォルト表紙
市場調査レポート
商品コード
1703293

ファーマコゲノミクス技術市場- 世界の産業規模、シェア、動向、機会、予測、治療分野別、技術別、地域別、競合別、2020-2030年

Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area, By Technology, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.36円
代理店手数料はかかりません

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

ファーマコゲノミクス技術市場- 世界の産業規模、シェア、動向、機会、予測、治療分野別、技術別、地域別、競合別、2020-2030年
出版日: 2025年04月11日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

ファーマコゲノミクス技術の世界市場規模は、2024年に76億米ドルとなり、予測期間中の年間平均成長率（CAGR）は8.45%で、2030年までに大きな節目を迎え、力強い成長を遂げると予測されています。

ヘルスケアを取り巻く環境が進化を続ける中、個別化医療は患者の予後を向上させ、副作用を最小限に抑えるための中心的存在になりつつあります。このシフトの最前線にあるのが薬理ゲノミクス（PGx）であり、個人の遺伝子プロファイルに基づいて薬物療法のカスタマイズを可能にする変革的な分野です。

市場概要
予測期間 2026-2030
市場規模：2024年 76億米ドル
市場規模：2030年 123億9,000万米ドル
CAGR：2025年～2030年 8.45%
急成長セグメント オンコロジー
最大市場 北米

ファーマコゲノミクスは、ゲノミクスの中の専門分野であり、遺伝子の変異が薬物の代謝や反応にどのように影響するかを研究します。個人のDNAは一人一人異なることから、このアプローチにより、患者が特定の薬物にどのように反応するかを予測する遺伝子マーカーの同定が容易になります。その結果、薬理ゲノミクスによってヘルスケアプロバイダーは最大限の有効性と安全性のために治療を調整することができ、一般化された治療モデルから精密医療へと移行します。

市場促進要因

慢性疾患の有病率の増加

主な市場課題

データの複雑さと統合の障壁

主な市場動向

市場の進化を促進する技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 ファーマコゲノミクス技術市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療領域別（腫瘍学（肺がん、乳がん、大腸がん、子宮頸がん、その他）、神経疾患、循環器疾患、免疫疾患、感染症、その他）
    • 技術別（PCR、in-situハイブリダイゼーション、免疫組織化学、シークエンシング、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のファーマコゲノミクス技術市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のファーマコゲノミクス技術市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域のファーマコゲノミクス技術市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米のファーマコゲノミクス技術市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのファーマコゲノミクス技術市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界のファーマコゲノミクス技術市場：SWOT分析

第14章 競合情勢

  • QIAGEN N.V.
  • GE HealthCare,
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • FOUNDATION MEDICINE, INC.
  • Thermo Fisher Scientific Inc.
  • Leica Biosystems Nussloch GmBH,
  • Pfizer Inc..

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 16370

Global Pharmacogenomics Technology market was valued at USD 7.60 billion in 2024 and is projected to experience robust growth, reaching significant milestones by 2030 with a compound annual growth rate (CAGR) of 8.45% over the forecast period. As the healthcare landscape continues to evolve, personalized medicine is becoming central to enhancing patient outcomes and minimizing adverse drug reactions. At the forefront of this shift is pharmacogenomics (PGx), a transformative field that enables the customization of drug therapies based on an individual's genetic profile.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.60 Billion
Market Size 2030USD 12.39 Billion
CAGR 2025-20308.45%
Fastest Growing SegmentOncology
Largest MarketNorth America

Pharmacogenomics, a specialized area within genomics, studies how genetic variations influence drug metabolism and response. Given that every individual's DNA is unique, this approach facilitates the identification of genetic markers that predict how patients will respond to specific medications. As a result, pharmacogenomics allows healthcare providers to tailor treatments for maximum effectiveness and safety, moving away from generalized treatment models toward precision medicine.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases globally is a primary catalyst for the growth of the pharmacogenomics technology market. Conditions such as cancer, cardiovascular disease, diabetes, and chronic respiratory disorders remain leading causes of mortality, collectively responsible for over 41 million deaths annually. Additionally, approximately one in three adults worldwide live with multiple chronic conditions, necessitating long-term and highly personalized treatment plans.

In 2022 alone, there were an estimated 20 million new cancer cases and 9.7 million related deaths, while 53.5 million individuals were within five years of a cancer diagnosis. These figures highlight the growing burden of chronic illness and the need for more effective and individualized therapeutic approaches.

Traditional treatment models often rely on trial-and-error prescribing, which can result in suboptimal outcomes and increased healthcare costs. Pharmacogenomics offers a solution by matching patients with the most appropriate medications based on their genetic makeup, thereby improving therapeutic efficacy and reducing adverse drug events. The economic implications are also significant-pharmacogenomics supports cost containment by decreasing the use of ineffective treatments and reducing hospitalizations due to drug-related complications. This makes it an attractive proposition for both public health systems and private payers, fueling broader industry adoption.

Key Market Challenges

Complexity of Data and Integration Barriers

One of the principal challenges in the pharmacogenomics sector lies in managing and integrating the vast amounts of complex data generated through genomic sequencing and drug response studies. Accurate prediction of drug efficacy and safety hinges on the effective analysis of these datasets, which requires sophisticated bioinformatics tools and specialized expertise. However, such capabilities are not uniformly distributed across global healthcare systems, creating disparities in implementation and limiting market penetration in certain regions.

Key Market Trends

Advancements in Technology Driving Market Evolution

Technological innovation continues to be a major growth enabler for the pharmacogenomics industry. High-throughput techniques such as next-generation sequencing (NGS) have revolutionized the field by enabling rapid, cost-effective analysis of entire genomes or targeted gene regions. NGS has dramatically improved the accuracy and efficiency of detecting clinically relevant genetic variants, expanding the potential for personalized drug therapy.

The proliferation of genomic data generated through NGS has necessitated the adoption of advanced analytical solutions. Machine learning and artificial intelligence (AI) have emerged as vital tools for interpreting complex datasets, identifying patterns, and predicting individual drug responses. These technologies are facilitating more informed decision-making for clinicians and accelerating the integration of pharmacogenomics into routine clinical practice.

Key Market Players

  • QIAGEN N.V.
  • GE HealthCare,
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • FOUNDATION MEDICINE, INC.
  • Thermo Fisher Scientific Inc.
  • Leica Biosystems Nussloch GmBH,
  • Pfizer Inc.

Report Scope:

In this report, the Global Pharmacogenomics Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmacogenomics Technology Market, By Therapeutics Area:

  • Oncology
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others

Pharmacogenomics Technology Market, By Technology:

  • PCR
  • In-situ Hybridization
  • Immunohistochemistry
  • Sequencing
  • Others

Pharmacogenomics Technology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmacogenomics Technology Market.

Available Customizations:

Global Pharmacogenomics Technology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Pharmacogenomics Technology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area (Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others), Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others)
    • 5.2.2. By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Pharmacogenomics Technology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutics Area
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmacogenomics Technology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutics Area
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Pharmacogenomics Technology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutics Area
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Pharmacogenomics Technology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutics Area
        • 6.3.3.2.2. By Technology

7. Europe Pharmacogenomics Technology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutics Area
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmacogenomics Technology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutics Area
        • 7.3.1.2.2. By Technology
    • 7.3.2. United Kingdom Pharmacogenomics Technology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutics Area
        • 7.3.2.2.2. By Technology
    • 7.3.3. Italy Pharmacogenomics Technology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutics Area
        • 7.3.3.2.2. By Technology
    • 7.3.4. France Pharmacogenomics Technology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutics Area
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Pharmacogenomics Technology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutics Area
        • 7.3.5.2.2. By Technology

8. Asia-Pacific Pharmacogenomics Technology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutics Area
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Pharmacogenomics Technology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutics Area
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Pharmacogenomics Technology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutics Area
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Pharmacogenomics Technology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutics Area
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Pharmacogenomics Technology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutics Area
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Pharmacogenomics Technology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutics Area
        • 8.3.5.2.2. By Technology

9. South America Pharmacogenomics Technology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutics Area
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pharmacogenomics Technology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutics Area
        • 9.3.1.2.2. By Technology
    • 9.3.2. Argentina Pharmacogenomics Technology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutics Area
        • 9.3.2.2.2. By Technology
    • 9.3.3. Colombia Pharmacogenomics Technology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutics Area
        • 9.3.3.2.2. By Technology

10. Middle East and Africa Pharmacogenomics Technology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutics Area
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pharmacogenomics Technology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutics Area
        • 10.3.1.2.2. By Technology
    • 10.3.2. Saudi Arabia Pharmacogenomics Technology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutics Area
        • 10.3.2.2.2. By Technology
    • 10.3.3. UAE Pharmacogenomics Technology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutics Area
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Pharmacogenomics Technology Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. QIAGEN N.V.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. GE HealthCare,
  • 14.3. Agilent Technologies, Inc.
  • 14.4. F. Hoffmann-La Roche Ltd
  • 14.5. FOUNDATION MEDICINE, INC.
  • 14.6. Thermo Fisher Scientific Inc.
  • 14.7. Leica Biosystems Nussloch GmBH,
  • 14.8. Pfizer Inc..

15. Strategic Recommendations

16. About Us & Disclaimer